<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="67866"><DrugName>nicotine + opipramol (transdermal patch, ADHD/CNS disorders), NeuroDerm</DrugName><DrugSynonyms><Name><Value>ND0801-A</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>nicotine co-formulation (transdermal patch, ADHD/CNS disorders), NeuroDerm</Value></Name><Name><Value>nicotine + opipramol (transdermal patch, ADHD/CNS disorders), NeuroDerm</Value></Name><Name><Value>ND-0801</Value></Name><Name><Value>nicotine + opipramol</Value></Name><Name><Value>54-11-5</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>315-72-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1020965">NeuroDerm Ltd</CompanyOriginator><CompaniesSecondary><Company id="1020965">NeuroDerm Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="67866" type="Drug"><TargetEntity id="707119" type="siDrug">ND-0801</TargetEntity></SourceEntity><SourceEntity id="1020965" type="Company"><TargetEntity id="5035524787" type="organizationId">Neuroderm Ltd</TargetEntity></SourceEntity><SourceEntity id="34" type="ciIndication"><TargetEntity id="F90" type="ICD10"></TargetEntity><TargetEntity id="10003736" type="MEDDRA"></TargetEntity><TargetEntity id="D001289" type="MeSH"></TargetEntity><TargetEntity id="-197354408" type="omicsDisease"></TargetEntity><TargetEntity id="87" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="60" type="ciIndication"><TargetEntity id="D002493" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="1166" type="Action"><TargetEntity id="5075" type="Mechanism">Nicotinic alpha3beta2 Receptor Ligands</TargetEntity><TargetEntity id="6568" type="Mechanism">Nicotinic Receptor Ligands</TargetEntity><TargetEntity id="5004" type="Mechanism">Nicotinic alpha6beta2alpha4beta2beta3 Receptor Ligands</TargetEntity><TargetEntity id="5001" type="Mechanism">Nicotinic alpha4beta2alpha5 Receptor Ligands</TargetEntity><TargetEntity id="15" type="Mechanism">Drugs Acting on Acetylcholine Receptors (Nicotinic)</TargetEntity><TargetEntity id="5147" type="Mechanism">Nicotinic alpha6beta2beta3 Receptor Ligands</TargetEntity><TargetEntity id="4996" type="Mechanism">Nicotinic alpha9alpha10 Receptor Ligands</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="34">Attention deficit hyperactivity disorder</Indication><Indication id="60">Central nervous system disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="1166">Nicotinic acetylcholine receptor modulator</Action></ActionsPrimary><ActionsSecondary><Action id="70">Anticonvulsant agent</Action><Action id="2941">Antidepressant</Action><Action id="2942">Anxiolytic</Action><Action id="2947">Antiparkinsonian</Action></ActionsSecondary><Technologies><Technology id="600">Patch formulation</Technology><Technology id="175">Drug combination</Technology><Technology id="558">Transdermal formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N3A</Code><Name>ANTI-EPILEPTICS</Name></Ephmra><Ephmra><Code>N5C</Code><Name>TRANQUILLISERS</Name></Ephmra><Ephmra><Code>N</Code><Name>CENTRAL NERVOUS SYSTEM</Name></Ephmra><Ephmra><Code>N3</Code><Name>ANTI-EPILEPTICS</Name></Ephmra><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-08-06T06:07:22.000Z</LastModificationDate><ChangeDateLast>2018-08-06T00:00:00.000Z</ChangeDateLast><AddedDate>2010-08-26T15:52:35.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1020965" linkType="Company"&gt;NeuroDerm&lt;/ulink&gt;, a subsidiary of &lt;ulink linkID="1035060" linkType="Company"&gt;Mitsubishi Tanabe Pharma&lt;/ulink&gt; was developing ND-0801 (ND-0801-A), a transdermal patch formulation of nicotine, which prevents desensitization of nicotinic receptors, and  opipramol, an axiolytic, for the potential treatment of attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD) in adults [&lt;ulink linkID="1126654" linkType="Reference"&gt;1126654&lt;/ulink&gt;], [&lt;ulink linkID="1146613" linkType="Reference"&gt;1146613&lt;/ulink&gt;], [&lt;ulink linkID="1563762" linkType="Reference"&gt;1563762&lt;/ulink&gt;], [&lt;ulink linkID="1676922" linkType="Reference"&gt;1676922&lt;/ulink&gt;], [&lt;ulink linkID="1972588" linkType="Reference"&gt;1972588&lt;/ulink&gt;].  In November 2010, a phase IIa trial was initiated in ADD/ADHD patients [&lt;ulink linkID="1146613" linkType="Reference"&gt;1146613&lt;/ulink&gt;]. In November 2011,  the drug was listed as being in preclinical development for other CNS disorders [&lt;ulink linkID="1238706" linkType="Reference"&gt;1238706&lt;/ulink&gt;]. In December 2016, development was ongoing [&lt;ulink linkID="1888739" linkType="Reference"&gt;1888739&lt;/ulink&gt;]. In November 2011, the company planned to advance the drug to a phase III trial for ADHD and  phase II and I trials for other disorders   [&lt;ulink linkID="1238706" linkType="Reference"&gt;1238706&lt;/ulink&gt;]; however, in July 2018, the drug was listed on the Mitsubishi Tanabe Pharma pipeline as being discontinued [&lt;ulink linkID="2058522" linkType="Reference"&gt;2058522&lt;/ulink&gt;], [&lt;ulink linkID="2060035" linkType="Reference"&gt;2060035&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In August 2010, an open-label, escalating-dose, phase I/II study (&lt;ulink linkID="68794" linkType="Protocol"&gt;NCT01174355&lt;/ulink&gt;; ND0801/001) was planned in patients with ADHD  in Israel, to assess the safety and tolerability of ND-0801. The study was expected to be initiated later that month and be complete by April 2012 [&lt;ulink linkID="1126654" linkType="Reference"&gt;1126654&lt;/ulink&gt;]. In November 2010, enrollment was initiated in an Israeli, phase IIa trial. A total of 45 ADD/ADHD patients would be enrolled. Safety, tolerability and optimal therapeutic dose would be assessed and cognitive improvement would be evaluated using standard cognition scale tests [&lt;ulink linkID="1146613" linkType="Reference"&gt;1146613&lt;/ulink&gt;]. By July 2015, interim results from 30-patients enrolled  displayed dose dependent improvement in attention and cognition followed by seven days of ND-0801 treatment with no observed serious side effects. NeuroDerm expected final results by the first half of 2015 [&lt;ulink linkID="1676922" linkType="Reference"&gt;1676922&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By November 2010, preclinical studies had demonstrated ND-0801 to prevent desensitization of nicotinic receptors [&lt;ulink linkID="1146613" linkType="Reference"&gt;1146613&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1020965">NeuroDerm Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="60">Central nervous system disease</Indication><StatusDate>2018-07-27T00:00:00.000Z</StatusDate><Source id="2058522" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020965">NeuroDerm Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="34">Attention deficit hyperactivity disorder</Indication><StatusDate>2018-07-27T00:00:00.000Z</StatusDate><Source id="2058522" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1020965">NeuroDerm Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="60">Central nervous system disease</Indication><StatusDate>2010-11-09T00:00:00.000Z</StatusDate><Source id="1146613" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1020965">NeuroDerm Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="34">Attention deficit hyperactivity disorder</Indication><StatusDate>2010-11-09T00:00:00.000Z</StatusDate><Source id="1146613" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1020965">NeuroDerm Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="34">Attention deficit hyperactivity disorder</Indication><StatusDate>2010-08-02T00:00:00.000Z</StatusDate><Source id="1126654" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01424"><Name>Nicotinic acetylcholine receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2058522" linkType="reference" linkID="2058522"&gt;2058522&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CN1CCC[C@H]1c2cccnc2</Smiles><Smiles>c1ccc2c(c1)C=Cc3ccccc3N2CCCN4CCN(CC4)CCO</Smiles><Smiles>CN1CCC[C@H]1c2cccnc2.c1ccc2c(c1)C=Cc3ccccc3N2CCCN4CCN(CC4)CCO</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="269539" number="WO-2009069126" title="Compositions comprising nicotinic agonists and methods of using same"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mitsubishi Chemical Holdings Corp" id="1022450"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>